For the acquiring company, AbbVie, the acquisition of Landos Biopharma represents a strategic move to enhance its portfolio, which could be viewed positively by investors. However, the impact on AbbVie's stock (ABBV) might be more nuanced, depending on the acquisition terms, cost, and how investors perceive the long-term benefits.

The announcement of an acquisition typically leads to an increase in the stock price of the company being acquired due to anticipated premium payments. In this case, Landos Biopharma's agreement with AbbVie is likely to have a positive short-term impact on LABP's stock price.